Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

BACKGROUND. Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. MATERIALS AND METHODS. This prospective, multi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Capdevila, Jaume, Teulé, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, García‐Carbonero, Rocío, Dotor, Emma, Matos, Ignacio, Custodio, Ana, Casanovas, Oriol, Salazar, Ramon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2018
Konular:
Endocrinology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324631/
https://ncbi.nlm.nih.gov/pubmed/29794066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0622
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller